Skip to main content

Coronavirus

15
Pipeline Programs
26
Companies
21
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
2
5
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
350%
Vaccine
350%
+ 26 programs with unclassified modality

Competitive Landscape

26 companies ranked by most advanced pipeline stage

Biocon
BioconIndia - Bangalore
1 program
1
EQ001Phase 31 trial
Active Trials
NCT04605926Withdrawn0Est. Jun 2021
Equillium
EquilliumCA - La Jolla
1 program
1
EQ001Phase 3
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
2 programs
1
1
bamlanivimab 7000mgPhase 2/3
EIDD-2801Phase 11 trial
Active Trials
NCT04392219Completed130Est. Aug 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
bamlanivimab 7000mgPhase 2/3
Sagent Pharmaceuticals
Sagent PharmaceuticalsIL - Schaumburg
1 program
1
bamlanivimab 7000mgPhase 2/3
Synairgen
SynairgenUK - Southampton
1 program
1
bamlanivimab 7000mgPhase 2/3
Prevail Therapeutics
1 program
1
bamlanivimab 7000mgPhase 2/31 trial
Active Trials
NCT04518410Completed4,044Est. Jun 2023
Syndax Pharmaceuticals
1 program
1
SNDX-6352Phase 21 trial
Active Trials
NCT04415073Terminated1Est. Jul 2020
Senhwa Biosciences
Senhwa BiosciencesCA - San Diego
1 program
1
SilmitasertibPhase 2Small Molecule1 trial
Active Trials
NCT04668209Terminated31Est. Oct 2022
AbelZeta Pharma
AbelZeta PharmaChina - Shanghai
2 programs
1
1
Mesenchymal stem cell exosomesPhase 1/2
MSCs-derived exosomesPhase 11 trial
Active Trials
NCT04276987Completed24Est. Jul 2020
Sandoz
SandozAustria - Kundl
1 program
1
RuxolitinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04581954Completed185Est. Sep 2023
Ridgeback Biotherapeutics
1 program
1
EIDD-2801Phase 1
Osivax
OsivaxFrance - Lyon
1 program
1
OVX033Phase 11 trial
Active Trials
NCT06128382Completed48Est. Nov 2024
CureVac
CureVacGermany - Tübingen
4 programs
CVnCoV 6 μgPHASE_21 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
CVnCoV VaccinePHASE_3Vaccine1 trial
Active Trials
NCT04515147Completed668Est. Feb 2022
NCT04838847Withdrawn0Est. Sep 2022
NCT04674189Completed2,357Est. Jun 2022
+1 more trials
Gylden Pharma
Gylden PharmaUK - Abingdon
2 programs
LD Vehicle-GNPPHASE_11 trial
PepGNP-COVID19PHASE_1_21 trial
Active Trials
NCT05113862Completed26Est. Sep 2022
NCT05633446Not Yet Recruiting110Est. Dec 2026
Innovation Pharmaceuticals
1 program
Aerosol BoxN/A1 trial
Active Trials
NCT04880668Completed122Est. Dec 2021
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
COVID-19 Community Research PartnershipN/A1 trial
Active Trials
NCT04342884Completed61,410Est. May 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Investigational IVD for coronavirusesN/A1 trial
Active Trials
NCT07221097Recruiting1,500Est. Aug 2026
Alliance Pharmaceuticals
1 program
Observation of patients with known, suspected, or at risk for COVID-19 infectionN/A1 trial
Active Trials
NCT04321811Completed5,000Est. Mar 2021
Akari Therapeutics
1 program
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19N/A1 trial
Active Trials
NCT04453527Completed72Est. May 2021
Aytu BioPharma
Aytu BioPharmaDENVER, CO
1 program
UV Light TreatmentN/A1 trial
Active Trials
NCT04572399Completed5Est. Dec 2020
Celularity
CelularityFLORHAM PARK, NJ
1 program
CYNK-001PHASE_1_21 trial
Active Trials
NCT04365101Unknown86Est. Jun 2022
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
RuxolitinibPHASE_1_2Small Molecule
Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
bamlanivimab 7000mgPHASE_2_3
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
bamlanivimab 7000mgPHASE_2_3
Bristol Myers Squibb
1 program
bamlanivimab 7000mgPHASE_2_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
CureVacCVnCoV Vaccine
BioconEQ001
Prevail Therapeuticsbamlanivimab 7000mg
Senhwa BiosciencesSilmitasertib
CureVacCVnCoV 6 μg
Syndax PharmaceuticalsSNDX-6352
Gylden PharmaPepGNP-COVID19
SandozRuxolitinib
CelularityCYNK-001
OsivaxOVX033
Gylden PharmaLD Vehicle-GNP
BioTherapeutics IncEIDD-2801
AbelZeta PharmaMSCs-derived exosomes

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 75,948 patients across 21 trials

NCT04838847CureVacCVnCoV Vaccine

A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19

Start: Oct 2021Est. completion: Sep 20220
Phase 3Withdrawn
NCT04860258CureVacCVnCoV Vaccine

COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

Start: Apr 2021Est. completion: Sep 2021129 patients
Phase 3Terminated
NCT04674189CureVacCVnCoV Vaccine

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Start: Dec 2020Est. completion: Jun 20222,357 patients
Phase 3Completed
NCT04605926BioconEQ001

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

Start: Nov 2020Est. completion: Jun 20210
Phase 3Withdrawn
NCT04518410Prevail Therapeuticsbamlanivimab 7000mg

ACTIV-2: A Study for Outpatients With COVID-19

Start: Aug 2020Est. completion: Jun 20234,044 patients
Phase 2/3Completed
NCT04668209Senhwa BiosciencesSilmitasertib

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

Start: Jan 2021Est. completion: Oct 202231 patients
Phase 2Terminated
NCT04515147CureVacCVnCoV 6 μg

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Start: Sep 2020Est. completion: Feb 2022668 patients
Phase 2Completed
NCT04415073Syndax PharmaceuticalsSNDX-6352

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Start: May 2020Est. completion: Jul 20201 patients
Phase 2Terminated
NCT05633446Gylden PharmaPepGNP-COVID19

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Start: Sep 2025Est. completion: Dec 2026110 patients
Phase 1/2Not Yet Recruiting
NCT04581954SandozRuxolitinib

Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Start: Oct 2020Est. completion: Sep 2023185 patients
Phase 1/2Completed
NCT04365101CelularityCYNK-001

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Start: May 2020Est. completion: Jun 202286 patients
Phase 1/2Unknown
NCT06128382OsivaxOVX033

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Start: Jan 2024Est. completion: Nov 202448 patients
Phase 1Completed
NCT05113862Gylden PharmaLD Vehicle-GNP

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Start: Jan 2022Est. completion: Sep 202226 patients
Phase 1Completed
NCT04392219BioTherapeutics IncEIDD-2801

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

Start: Apr 2020Est. completion: Aug 2020130 patients
Phase 1Completed
NCT04276987AbelZeta PharmaMSCs-derived exosomes

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia

Start: Feb 2020Est. completion: Jul 202024 patients
Phase 1Completed
NCT07221097Angeles TherapeuticsInvestigational IVD for coronaviruses

Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

Start: Sep 2025Est. completion: Aug 20261,500 patients
N/ARecruiting
NCT04880668Innovation PharmaceuticalsAerosol Box

Impact of Aerosol Box Use on Healthcare Provider Contamination

Start: Jun 2021Est. completion: Dec 2021122 patients
N/ACompleted
NCT04572399Aytu BioPharmaUV Light Treatment

UVA Light Device to Treat COVID-19

Start: Oct 2020Est. completion: Dec 20205 patients
N/ACompleted
NCT04453527Akari TherapeuticsThe CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19

Start: May 2020Est. completion: May 202172 patients
N/ACompleted
NCT04342884Human BioSciencesCOVID-19 Community Research Partnership

COVID-19 Community Research Partnership

Start: Apr 2020Est. completion: May 202261,410 patients
N/ACompleted
NCT04321811Alliance PharmaceuticalsObservation of patients with known, suspected, or at risk for COVID-19 infection

Behavior, Environment And Treatments for Covid-19

Start: Mar 2020Est. completion: Mar 20215,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 75,948 patients
26 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.